A systematic scoping review of multidisciplinary cancer team and decision-making in the management of men with advanced prostate cancer

Abstract

Purpose

The early diagnosis of prostate cancer and subsequent access to the treatment options helps to achieve optimal cancer outcomes. As the treatment options for patients with advanced prostate cancer continues to evolve, patients need to access a multidisciplinary team (MDT) meeting to receive best-practice care.

Methods

In this paper a MEDLINE review was performed to assess clinical decision making in the context of MDT discussions for patients with advanced prostate cancer.

Results

From 441 returned articles and abstracts, 50 articles were assessed for eligibility and 16 articles included for analysis. Sixteen articles were identified, 9 of the 16 articles used quantitative methodology including three retrospective analysis of clinical registry data, patient medical records and/or MDT meeting notes and three cross-sectional surveys. Other study designs included one observation study and one study using a combination of qualitative and quantitative methodologies and one mini-review. There were also four editorials included in the review and two consensus statements.

Conclusion

This paper highlights the important role the inter-disciplinary MDT has on shared decision making for men with advanced prostate cancer. The application of MDT care is a rapidly growing trend in uro-oncology and an efficient MDT service requires further research to assess its efficiency so that it may expand through all aspect of uro-oncology.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Murphy DG, Hofman MS, Azad A, Violet J, Hicks RJ, Lawrentschuk N (2019) Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. BJU Int. https://doi.org/10.1111/bju.14814

  2. 2.

    Mottet N, Bergh RCN Van Den, Vice-chair PC, Santis M De, Gillessen S, Govorov A, et al (2018) EAU-ESUR-ESTRO-SIOG Guidelines on Prostate Cancer/Guias Europeas. Eur Assoc Urol. ISBN 978-94-92671-05-9

  3. 3.

    Horwich A, Parker C, Bangma C, Kataja V (2010) Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. Suppl 5:v129–v133. https://doi.org/10.1093/annonc/mdq174

    Article  PubMed  Google Scholar 

  4. 4.

    Hurwitz LM, Cullen J, Elsamanoudi S, Kim DJ, Hudak J, Colston M, et al (2016) A prospective cohort study of treatment decision-making for prostate cancer following participation in a multidisciplinary clinic. Urol Oncol 34(5):233.e17–233.e25. https://doi.org/10.1016/j.urolonc.2015.11.014

    Article  Google Scholar 

  5. 5.

    Borras JM, Albreht T, Audisio R, Briers E, Casali P, Esperou H et al (2014) Policy statement on multidisciplinary cancer care. Eur J Cancer 50(3):475–480. https://doi.org/10.1016/j.ejca.2013.11.01

    Article  PubMed  Google Scholar 

  6. 6.

    Huay C (2020) Surgical perspectives of locally advanced prostate cancer. World J Urol (In Press)

  7. 7.

    Sathianathen NJ, Koschel S, Thangasamy IA, Teh J, Alghazo O, Butcher G et al (2019) Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur Urol 77(3):365–372. https://doi.org/10.1016/j.eururo.2019.09.004

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Hess-Busch Y, Hadaschik B, Hess J (2019) M0CRPC overview of management options. World J Urol. https://doi.org/10.1007/s00345-019-02997-z

    Article  PubMed  Google Scholar 

  9. 9.

    Azad A (2020) Metastatic hormone sensitive Pca: selection of systemic treatment options. World J Urol (In Press)

  10. 10.

    Walz J (2020) Metastatic hormone sensitive Pca: local treatment strategies. World J Urol (In Press)

  11. 11.

    Montorsi F (2020) On being sick and tired. Eur Urol Oncol 3(1):7–9. https://doi.org/10.1016/j.euo.2019.08.016

    Article  PubMed  Google Scholar 

  12. 12.

    Bravi CA, Tin A, Vertosick E, Mazzone E, Bandini M, Dell’Oglio P et al (2020) Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy. Urol Oncol 38(4):204–209. https://doi.org/10.1016/j.urolonc.2019.09.018

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Fossati N et al (2019) Contemporary Trends and survival outcomes after aborted radical prostatectomy in lymph node metastatic prostate cancer patients. Eur Urol Focus 5(3):381–388. https://doi.org/10.1016/j.euf.2018.01.009

    Article  PubMed  Google Scholar 

  14. 14.

    Lowrance WT, Murad MH, Oh WK, Jarrard DF, Resnick MJ, Cookson MS (2018) Castration-resistant prostate cancer: AUA guideline amendment 2018. J Urol 200(6):1264–1272. https://doi.org/10.1016/j.juro.2018.07.090

    Article  PubMed  Google Scholar 

  15. 15.

    Arksey H, O’Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol Theory Pract 8(1):19–32. https://doi.org/10.1080/1364557032000119616

    Article  Google Scholar 

  16. 16.

    Colquhoun HL, Levac D, O’Brien KK, Straus S, Tricco AC, Perrier L et al (2014) Scoping reviews: time for clarity in definition, methods, and reporting. J Clin Epidemiol 67(12):1291–1294. https://doi.org/10.1016/j.jclinepi.2014.03.013

    Article  PubMed  Google Scholar 

  17. 17.

    Rourke K (2018) Getting to know each other: Integrating radiation and medical oncology training in urology (and urology training in oncology). Can Urol Assoc J 12(10):326–327. https://doi.org/10.5489/cuaj.5607

    Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Heidenreich A (2019) Multidisciplinary team meetings for prostate cancer treatment: we can do much better in daily life. Oncol Res Treatm 42(7–8):363–365. https://doi.org/10.1159/000500426

    Article  Google Scholar 

  19. 19.

    Hoge C, Sidana A (2020) Multidisciplinary clinics: a possible means to help to eliminate racial disparities in prostate cancer. Cancer 126(12):2938–2939. https://doi.org/10.1002/cncr.32841

    Article  PubMed  Google Scholar 

  20. 20.

    Onukwugha E, Mullins CD, Doren Hsu V, Seal B, Hussain A (2011) Effect of urologists and medical oncologists on treatment of elderly men with stage IV prostate cancer. Urology 77(5):1088–1095. https://doi.org/10.1016/j.urology.2010.11.059

    Article  PubMed  Google Scholar 

  21. 21.

    Zereshkian A, Cao X, Puts M, Dawdy K, Di Prospero L, Alibhai S et al (2019) Do Canadian radiation oncologists consider geriatric assessment in the decision-making process for treatment of patients 80 years and older with non-metastatic prostate cancer?—national survey. J Geriatr Oncol 10(4):659–665. https://doi.org/10.1016/j.jgo.2019.01.015

    Article  PubMed  Google Scholar 

  22. 22.

    Poon DMC, Ma WK, Chan TW, Ho FKL, Ho LY, Leung AKC et al (2019) Management of advanced prostate cancer in Hong Kong: insights from an APCCC-derived survey. Asia Pac J Clin Oncol Suppl 6:8–13. https://doi.org/10.1111/ajco.13247

    Article  Google Scholar 

  23. 23.

    Saad F, Canil C, Finelli A, Hotte SJ, Malone S, Shayegan B et al (2019) A A Canadian consensus forum on the management of patients with advanced prostate cancer. Can Urol Assoc J 14(4):E137–E149. https://doi.org/10.5489/cuaj.6082

    Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Brown B, Young J, Smith DP, Kneebone AB, Brooks AJ, Egger S et al (2018) A multidisciplinary team-oriented intervention to increase guideline recommended care for high-risk prostate cancer: a stepped-wedge cluster randomised implementation trial. Implement Sci 13(1):43. https://doi.org/10.1186/s13012-018-0733-x

    Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Betschart P, Babst C, Schmid S, Rothermundt C, Abt D, Schwab C et al (2019) Shared decision-making for patients with advanced urological malignancies: evaluation of a joint urological-oncological clinic model. Oncol Res Treat 42(7–8):366–374. https://doi.org/10.1159/000499721

    Article  PubMed  Google Scholar 

  26. 26.

    Knipper S, Sadat-Khonsari M, Boehm K, Mandel P, Budäus L, Steuber T et al (2019) Impact of adherence to multidisciplinary recommendations for adjuvant treatment in radical prostatectomy patients with high risk of recurrence. Clin Genitourin Cancer 18(2):e112–e121. https://doi.org/10.1016/j.clgc.2019.09.007

    Article  PubMed  Google Scholar 

  27. 27.

    Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S et al (2020) Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer 126(3):506–514. https://doi.org/10.1002/cncr.32570

    Article  PubMed  Google Scholar 

  28. 28.

    De Luca S, Fiori C, Tucci M, Poggio M, Allis S, Bollito E, Solitro F, Passera R, Buttigliero CPF (2019) Prostate cancer management at an Italian tertiary referral centre: does multidisciplinary team meeting influence diagnostic and therapeutic decision-making process? A snapshot of the everyday clinical practice. Minerva Urol Nefrol 71(6):576–582. https://doi.org/10.23736/S0393-2249.19.03231-4

    Article  PubMed  Google Scholar 

  29. 29.

    Herlemann A, Washington SL, Cooperberg MR (2019) Health care delivery for metastatic hormone-sensitive prostate cancer across the globe. Eur Urol Focus 5(2):155–158. https://doi.org/10.1016/j.euf.2018.12.003

    Article  PubMed  Google Scholar 

  30. 30.

    Brausi M, Hoskin P, Andritsch E, Banks I, Beishon M, Boyle H et al (2020) ECCO essential requirements for quality cancer care: prostate cancer. Crit Rev Oncol Hematol 148:102861. https://doi.org/10.1016/j.critrevonc.2019.102861

    Article  PubMed  Google Scholar 

  31. 31.

    Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A et al (2020) Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019[formula presented]. Eur Urol 77(4):508–547. https://doi.org/10.1016/j.eururo.2020.01.012

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Thangasamy IA, Kwan EM, Teh J, Sathianathen N, Alghazo O, Siva S et al (2019) Novel agents for metastatic hormone-sensitive prostate cancer—a practice guide for urologists. BJU Int 125(3):342–345. https://doi.org/10.1111/bju.14936

    Article  PubMed  Google Scholar 

  33. 33.

    Rao K, Manya K, Azad A, Lawrentschuk N, Bolton D, Davis ID et al (2014) Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre—impact on clinical decision-making and implications for patient inclusion. BJU Int 114(Suppl 1):50–4. https://doi.org/10.1111/bju.12764

    Article  PubMed  Google Scholar 

  34. 34.

    Butcher HSP (2018) Patient engagement and empowerment driving patient centred care. In: In Velikova G, Fallowfield L, Younger J et al (eds) Problem solving in patient centred and integrated cancer care. EBN Health, Witney, pp 24–30

  35. 35.

    Bultijnck R, Deforche B, Borrey N et al (2020) Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial. World J Urol. https://doi.org/10.1007/s00345-020-03098-y

    Article  PubMed  Google Scholar 

  36. 36.

    Han S, Woo S, Kim YJ, Suh CH (2018) Impact of 68 Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 74(2):179–190. https://doi.org/10.1016/j.eururo.2018.03.030

    CAS  Article  PubMed  Google Scholar 

  37. 37.

    Van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B et al (2016) 68 Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int 117(5):732–739. https://doi.org/10.1111/bju.13397

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I et al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77(4):403–417. https://doi.org/10.1016/j.eururo.2019.01.049

    Article  PubMed  Google Scholar 

  39. 39.

    De Bruycker A, Tran PT, Achtman AH et al (2020) Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries. World J Urol. https://doi.org/10.1007/s00345-019-03063-4

    Article  PubMed  Google Scholar 

  40. 40.

    Sundi D, Cohen JE, Cole AP, Neuman BP, Cooper J, Faisal FA et al (2015) Establishment of a new prostate cancer multidisciplinary clinic: format and initial experience. Prostate 75(2):191–199. https://doi.org/10.1002/pros.22904

    Article  PubMed  Google Scholar 

  41. 41.

    Kinnear N, Smith R, Hennessey DB, Bolton D, Sengupta S (2017) Implementation rates of uro-oncology multidisciplinary meeting decisions. BJU Int 120(Suppl 3):15–20. https://doi.org/10.1111/bju.13892

    Article  PubMed  Google Scholar 

  42. 42.

    Prades J, Remue E, van Hoof E, Borras JM (2015) Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy 119(4):464–474. https://doi.org/10.1016/j.healthpol.2014.09.006

    Article  PubMed  Google Scholar 

  43. 43.

    Pillay B, Wootten AC, Crowe H, Corcoran N, Tran B, Bowden P et al (2016) The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature. Cancer Treatm Rev 42:56–72. https://doi.org/10.1016/j.ctrv.2015.11.007

    Article  Google Scholar 

  44. 44.

    Selby P, Liu L, Downing A, Banks I, Wilson RRS, Meunier F, Rochon J, Morris E, Seymour M, Gregory WML, Boaz A (2019) How can clinical research improve European health outcomes in cancer? J cancer Surg 20:100182

  45. 45.

    Shore ND (2013) Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist. Prostate Cancer and Prostatic Dis 16(1):1–6. https://doi.org/10.1038/pcan.2012.23

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

A Holmes: Project development, Data Collection, Manuscript writing. BD Kelly: data collection, manuscript writing. M Perera: data collection, manuscript writing. RS Eapen: project development, manuscript writing/editing. DM Bolton: project development, manuscript writing/editing. N Lawrentschuk: project development, data collection, manuscript writing.

Corresponding author

Correspondence to N. Lawrentschuk.

Ethics declarations

Conflict of interest

None to declare.

Research involving Human Participants and/or Animals

Not relevant.

Informed consent

Not relevant.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Holmes, A., Kelly, B.D., Perera, M. et al. A systematic scoping review of multidisciplinary cancer team and decision-making in the management of men with advanced prostate cancer. World J Urol (2020). https://doi.org/10.1007/s00345-020-03265-1

Download citation

Keywords

  • Prostate neoplasm
  • Prostate
  • Interdisciplinary communication
  • Disease management
  • Urology
  • Clinical oncology